Zobrazeno 1 - 4
of 4
pro vyhledávání: '"S.A. Dantsoho"'
Autor:
S.A. Dantsoho, N. Okoro, J. Abdulazeez, E.J. Nwagboso, T.C. Orjiakor, Z.D. Gata, Runcie C.W. Chidebe, R. Okonkwo, T.E. Ogugua, P. Emezue, N. Lyonga
Publikováno v:
Journal of Global Oncology. 4:248s-248s
Background and context: Nigeria has been rated the 1st nation in Africa and 5th in the world with highest cervical cancer deaths with >26 women dying daily. Breast cancer incidence is higher with 90 new cases per 100,000 women annually in some wester
Autor:
E.J. Nwagboso, R. Gimba, R. Dada, E. Adamu, O. Yahaya, C. Igbokwe, T.O. Nwosu, A. Ademola, A. Biose, P. Emezue, I. Ikechukwu, M.-G. Orji, F. Joseph, B.S. Adesoye, T.C. Orjiakor, C. Onwere, O. Nwabueze, U. Amadi-Obi, R. Agbi, Khadijat Banwo-Fatai, C. Onyekachi, S. Gimba, N.C. Ikeagwu, I. Oriaku, J.N. Ezenwaanne, V. Okenwa, J. Abdulazeez, Runcie C.W. Chidebe, I.M. Alimi, S.A. Dantsoho, F. Ononogbu, G. Nwodilae, N. Okoro
Publikováno v:
Journal of Global Oncology. 4:246s-246s
Background and context: Cancer diagnosis comes with a lot of challenges. It is a huge burden to the patient, family, and community; subjecting them to financial crisis, emotional distress, dearth of self-esteem, and physiologic deformations. From a p
Autor:
I. Iriyo, C.D. Anunobi, D. Atakere, A. Hafees, S.A. Dantsoho, N. Okoro, H. Dogo, I.O. Okoye, C. Ugwuoke, SO Ikuerowo, OF Emelumadu, J. Abdulazeez, Runcie C.W. Chidebe, David W. Lounsbury, N. Okwuegbunam, G. Achor, T.C. Orjiakor, O. Emeralds, Fabio Y. Moraes, Nkiru N. Ezeama, Kelechi Eguzo
Publikováno v:
Journal of Global Oncology. 4:238s-238s
Background and context: In Nigeria, cancer leads to >72,000 deaths per annum (30,924 for male and 40,647 for female). This number is set to increase given that there are 102,000 new cases of cancer every year. The estimated incidence for prostate can
Autor:
S.A. Dantsoho, Tochukwu Charles Orjiako, S. Gimba, N. Oriaku, Khadijat Banwo-Fatai, E.J. Nwagboso, P. Emezue, M.-G. Orji, T.O. Nwosu, N. Okoro, R. Agbi, J. Abdulazeez, Runcie C.W. Chidebe
Publikováno v:
Journal of Global Oncology. 4:155s-155s
Background and context: Several studies showed that the use of the recombinant monoclonal antibody trastuzumab, in addition to adjuvant chemotherapy, for breast cancer with overexpression of the HER-2 protein or amplification of the HER-2/neu gene re